← Patent-cliff monitor small molecule ONPATTRO PATISIRAN SODIUM
Loss of exclusivity August 2035 latest FDA-listed patent expiry
Drug detail Brand name ONPATTRO Active ingredient PATISIRAN SODIUM Strength EQ 10MG BASE/5ML (EQ 2MG BASE/ML) Dosage form SOLUTION Route INTRAVENOUS Modality Small molecule FDA approval August 2018 Marketing status RX
Listed patents Patent Expires Type 11079379 August 2035 substance, product 8168775 August 2032 substance, product 8158601 November 2030 product 8802644 October 2030 product 8741866 October 2029 use U-2378 9234196 October 2029 product 10240152 October 2029 substance, product 8822668 April 2029 product 8058069 April 2029 product 11141378 April 2029 product 8492359 April 2029 product 9364435 April 2029 product 8642076 October 2027 product
Regulatory exclusivity Code Expires M-270 January 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.